Login / Signup

Short Treatment of 42 Days with Oral GS-441524 Results in Equal Efficacy as the Recommended 84-Day Treatment in Cats Suffering from Feline Infectious Peritonitis with Effusion-A Prospective Randomized Controlled Study.

Anna-M Zuzzi-KrebitzKatharina BuchtaMichèle BergmannDaniela KrentzKatharina ZwicklbauerRoswitha DorschGerhard WessAndrea FischerKaspar MatiasekAnne HönlSonja FiedlerLaura KolbergRegina Hofmann-LehmannMarina Luisa MeliAndrea Monika SpiriA Katrin Helfer-HungerbuehlerSandra FeltenYury ZablotskiMartin AlbererUlrich von BothKatrin Hartmann
Published in: Viruses (2024)
In the past, feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) was considered fatal. Today, highly efficient drugs, such as GS-441524, can lead to complete remission. The currently recommended treatment duration in the veterinary literature is 84 days. This prospective randomized controlled treatment study aimed to evaluate whether a shorter treatment duration of 42 days with oral GS-441524 obtained from a licensed pharmacy is equally effective compared to the 84-day regimen. Forty cats with FIP with effusion were prospectively included and randomized to receive 15 mg/kg of GS-441524 orally every 24h (q24h), for either 42 or 84 days. Cats were followed for 168 days after treatment initiation. With the exception of two cats that died during the treatment, 38 cats (19 in short, 19 in long treatment group) recovered with rapid improvement of clinical and laboratory parameters as well as a remarkable reduction in viral loads in blood and effusion. Orally administered GS-441524 given as a short treatment was highly effective in curing FIP without causing serious adverse effects. All cats that completed the short treatment course successfully were still in complete remission on day 168. Therefore, a shorter treatment duration of 42 days GS-441524 15 mg/kg can be considered equally effective.
Keyphrases
  • systematic review
  • highly efficient
  • coronavirus disease
  • study protocol
  • replacement therapy
  • disease activity
  • phase iii